摘要
以生物制药产业为背景,采取案例研究方法,瞄准沙利度胺、伟哥等四种经历失败重获新生的创新药物为研究对象,回溯其"失败-成功"的重生过程,抽象归纳"科学家(大学、科研院所)—大企业合作-核心公司""科学家(专家型公司)—核心公司—专家型公司逐步内化为核心公司"及"科学家(核心公司)—核心公司全面行动"三种典型挽救路径,进而针对生物制药创新各方及失败药物挽救各参与方提出多种管理启示。
Under the background of biotechnology pharmaceutical industries, the paper takes a case study method, aiming at four kinds of innovative drugs that have failed to regenerate, such as Thalidomide and Viagra, backtracks the rebirth process of "failure and success", and abstractly sums up three typical rescue paths such as "Scientists(universities, scientific research institutes)-Big Enterprise Cooperation-Core Company","Scientist(Expert Company)-Core Company-Expert Company which is then gradually internalized into Core Company " and "Scientist(Core Company)– its Comprehensive Action ". At last, multiple management revelations for all parties involved in biopharmaceutical innovation and failed drug recovery are put forward.
作者
董晓东
李天柱
宋丹荣
Dong Xiaodong;Li Tianzhu;Song Danrong(School of Business Administration,University of Science and Technology Liaoning,Anshan 114051,China)
出处
《科技管理研究》
CSSCI
北大核心
2019年第6期128-135,共8页
Science and Technology Management Research
基金
国家自然科学基金项目"技术创新失败的挽救机制研究"(71772082)
辽宁省社会科学基金项目"政府与社会资本合作(PPP)项目的社会公众参与研究"(L15BGL005)
关键词
生物制药
挽救路径
管理启示
biopharmaceuticals
rescue path
management revelations
